{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-012181","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2025-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.450805+00:00","generated_at":"2026-05-20T14:44:42.976937+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vivos Therapeutics enters $1.1M convertible note to fund pending SCN acquisition","bullets":["$1.1M principal convertible note to V-Co Investors 2 LLC; net funding $1M after $100k fee.","Zero interest unless default; default rate 15% p.a.; secured by equipment only on default.","Converts automatically into equity of subsequent financing expected at SCN closing (target July 31, 2025).","Proceeds to fund previously announced acquisition of The Sleep Center of Nevada.","V-Co is affiliate of existing investor New Seneca Partners Inc."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-012181","json":"https://secwatch.observer/filing/0001641172-25-012181.json","markdown":"https://secwatch.observer/filing/0001641172-25-012181.md","text":"https://secwatch.observer/filing/0001641172-25-012181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000164117225012181/0001641172-25-012181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000164117225012181/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T14:44:42.976937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e761b5b212912a1e8c2f3a3fe5b1282de5b8cb4","claim":"Vivos Therapeutics, Inc. incurred convertible notes of $1,100,000 with V-Co Investors 2 LLC at 0% (15% per annum upon Event of Default) maturing No fixed maturity date; convertible prior to Outside Date or repayable after Outside Date.","evidence_excerpt":"On May 21, 2025, Vivos Therapeutics, Inc. (the “ Company ”) entered into a convertible promissory note in favor of V-Co Investors 2 LLC (“ V-Co ”) in the principal amount of $1,100,000 (the “ Note ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000164117225012181/0001641172-25-012181-index.htm","confidence":0.7,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$1,100,000"},{"label":"Counterparty","value":"V-Co Investors 2 LLC"},{"label":"Rate","value":"0% (15% per annum upon Event of Default)"},{"label":"Maturity","value":"No fixed maturity date; convertible prior to Outside Date or repayable after Outside Date"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}